Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Editas Medicine, Inc.NASDAQ: EDIT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$51.67M, compared with -$107.56M a year earlier.
Context
- Net debt amounted to 34.6% of total assets at the end of Q1 FY2026, down 6.2 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +52.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (69.94M) USD
- Year-over-year change
- +27.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (69.94M) | +27.5% |
| FY2024 | 2024-12-31 | (96.51M) | -28.5% |
| FY2023 | 2023-12-31 | (75.11M) | +23.0% |
| FY2022 | 2022-12-31 | (97.58M) | +44.9% |
| FY2021 | 2021-12-31 | (177.14M) | — |
Net Debt vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's Mar 2026 net debt of -$51.67M is the 6th highest of the 9 companies compared; the peer median is -$4.98M.
- Its year-over-year change of +52.0% is the 5th highest of 9, against a peer median of +35.3%.
- Net debt amounts to 34.6% of total assets for EDIT, versus a peer median of 13.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $587.8M | +416.6% | +7.3% | 23.0% | |
| Mar 2026 | $50.41M | +72.2% | — | 17.1% | |
| Jun 2026 | $27.53M | +121.6% | — | 2.0% | |
| Mar 2026 | $14.89M | +566.3% | — | 10.0% | |
| Mar 2026 | -$24.85M | -1.6% | — | 8.7% | |
| Mar 2026 | -$51.67M | +52.0% | — | 34.6% | |
| Mar 2026 | -$54.21M | -610.7% | — | 7.1% | |
| Mar 2026 | -$70.9M | -49.4% | — | 49.3% | |
| Mar 2026 | -$183.89M | -79.2% | — | 98.3% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding EDIT) | -$4.98M | +35.3% | +7.3% | 13.5% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 203.52M | 141.52M | 123.65M | 131.54M | 146.65M |
| Short-term Investments | 296.33M | 202.75M | 199.46M | 138.37M | 0 |
| Net Receivables | 267K | 5.15M | 10.19M | 16.27M | 15.18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.34M | 7.53M | 3.14M | 2.07M |
| Total Current Assets | 507.31M | 356.75M | 340.83M | 289.32M | 163.9M |
| Property, Plant & Equipment (Net) | 43.29M | 59.22M | 45.71M | 47.05M | 19.66M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 120.07M | 93.1M | 104.02M | 3.88M | 2.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.81M | 5.25M | 8.59M | 1.35M | 276K |
| Total Non-current Assets | 170.17M | 157.57M | 158.32M | 52.27M | 22.64M |
| Total Assets | 677.48M | 514.32M | 499.15M | 341.59M | 186.53M |
| Account Payables | 5.05M | 9.51M | 8.27M | 5.49M | 2.61M |
| Short-term Debt | 0 | 0 | 12M | 0 | 11.03M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.33M | 8.22M | 8.22M | 11.22M | 44.51M |
| Other Current Liabilities | 10.16M | 10.14M | (723K) | 21.99M | (11.9M) |
| Total Current Liabilities | 46.88M | 60.11M | 63.22M | 77.23M | 46.25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 53.61M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 60.89M | 60.67M | 60.67M | 106.64M | 44.51M |
| Other Non-current Liabilities | 0 | 0 | 1.8M | 3.07M | 2.82M |
| Total Non-current Liabilities | 76.96M | 93.53M | 86.84M | 130.09M | 113M |
| Total Liabilities | 123.84M | 153.64M | 150.06M | 207.32M | 159.25M |
| Common Stock | 7K | 7K | 8K | 8K | 10K |
| Retained Earnings | (857.7M) | (1.08B) | (1.23B) | (1.47B) | (1.63B) |
| Accumulated OCI | (493K) | (3.6M) | 198K | 268K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 553.64M | 360.68M | 349.1M | 134.27M | 27.29M |
| Total Debt | 26.38M | 43.95M | 48.54M | 35.03M | 76.71M |
| Net Debt | (177.14M) | (97.58M) | (75.11M) | (96.51M) | (69.94M) |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.